慢性恰加斯心脏病管理:从病因到心肌病治疗
恰加斯心脏病由克氏锥虫感染引起,表型异质,预后较其他病因心肌病差,心源性猝死为主要死因之一;多数患者表现为弥漫性心肌炎伴纤维化和肥厚。药物与抗心律失常治疗多借鉴其他病因证据,心脏移植为难治性病例的有效选择,植入式心律转复除颤器用于预防继发性心源性猝死,特异性病因治疗应重新评估并限于特定患者。
要点
- 克氏锥虫感染早期诊断至关重要,多数生物标志物对感染不特异。
- 恰加斯心脏病患者预后较其他病因差,心源性猝死是重要死亡方式。
- 药物与抗心律失常治疗多基于其他病因证据,心脏移植为确立的难治性治疗选择。
核心结论
- 恰加斯心脏病的理解与管理需改进,包括开展随机试验。
主要发现
- 克氏锥虫感染在拉丁美洲流行,正成为全球健康负担。
- 恰加斯心脏病患者预后较其他病因心肌病更差,心源性猝死是重要死亡方式。
- 多数患者显示弥漫性心肌炎伴纤维化和肥厚,重构过程可能与病因机制和神经激素激活相关。
临床怎么用
- 早期诊断克氏锥虫感染至关重要,但多数生物标志物对感染不特异。
- 特异性病因治疗应重新评估并保留给特定患者。
- 植入式心律转复除颤器用于预防继发性心源性猝死。
- 心脏移植是难治性恰加斯心脏病的确立且有价值的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trypanosoma cruzi (T. cruzi) infection is endemic in Latin America and is becoming a worldwide health burden. It may lead to heterogeneous phenotypes. Early diagnosis of T. cruzi infection is crucial. Several biomarkers have been reported in Chagas heart disease (ChHD), but most are nonspecific for T. cruzi infection. Prognosis of ChHD patients is worse compared with other etiologies, with sudden cardiac death as an important mode of death. Most ChHD patients display diffuse myocarditis with fibrosis and hypertrophy. The remodeling process seems to be associated with etiopathogenic mechanisms and neurohormonal activation. Pharmacological treatment and antiarrhythmic therapy for ChHD is mostly based on results for other etiologies. Heart transplantation is an established, valuable therapeutic option in refractory ChHD. Implantable cardioverter-defibrillators are indicated for prevention of secondary sudden cardiac death. Specific etiological treatments should be revisited and reserved for select patients. Understanding and management of ChHD need improvement, including development of randomized trials.
引用
- Bocchi EA, Bestetti RB, Scanavacca MI, et al. Chronic Chagas Heart Disease Management: From Etiology to Cardiomyopathy Treatment. J Am Coll Cardiol. 2017. PMID: 28911515. doi:10.1016/j.jacc.2017.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。